Loading...
•
Dec 31, 2021
Nuvation Bio Q4 2021 Earnings Report
Nuvation Bio reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update.
Key Takeaways
Nuvation Bio reported a net loss of $25.1 million, or $(0.12) per share, for the three months ended December 31, 2021. As of December 31, 2021, the company had cash, cash equivalents and marketable securities of $765.4 million.
FDA Fast Track Designation and multiple IND applications accepted for lead candidate NUV-422
Multiple milestones expected in 2022 for broad pipeline of potential product candidates
Cash, cash equivalents and marketable securities of $765.4 million as of December 31, 2021
FDA clearance of IND applications for NUV-422 for the treatment of advanced breast cancer and prostate cancer.
Nuvation Bio
Nuvation Bio
Forward Guidance
Nuvation Bio anticipates that subsequent events and developments will cause Nuvation Bio’s assessments to change. However, while Nuvation Bio may elect to update these forward-looking statements at some point in the future, Nuvation Bio specifically disclaims any obligation to do so.